News
KNSA
16.95
-2.92%
-0.51
Weekly Report: what happened at KNSA last week (0408-0412)?
Weekly Report · 2d ago
Weekly Report: what happened at KNSA last week (0401-0405)?
Weekly Report · 04/08 09:11
KINIKSA PHARMACEUTICALS LTD <KNSA.O>: WEDBUSH RAISES TARGET PRICE TO $30 FROM $28
Reuters · 04/03 04:19
Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Goldman Sachs
TipRanks · 04/02 18:55
Kiniksa Pharmaceuticals Advances Clinical Trials and Ensures Positive Cash Flow
TipRanks · 04/02 11:42
KINIKSA PHARMACEUTICALS LTD: ABIPRUBART DEVELOPMENT IN SJOGREN'S DISEASE FULLY FUNDED THROUGH PHASE 3
Reuters · 04/02 11:32
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024. Company expects to remain cash flow positive on an annual basis within current operating plan. AbipRubart development in S jogren's disease fully funded through Phase 3.
Barchart · 04/02 06:30
Weekly Report: what happened at KNSA last week (0325-0329)?
Weekly Report · 04/01 09:11
Weekly Report: what happened at KNSA last week (0318-0322)?
Weekly Report · 03/25 09:11
World’s first pig-to-human kidney transplant performed in U.S
Seeking Alpha · 03/21 16:56
Weekly Report: what happened at KNSA last week (0311-0315)?
Weekly Report · 03/18 09:11
Weekly Report: what happened at KNSA last week (0304-0308)?
Weekly Report · 03/11 09:11
5 Biotech Stocks With 26% Upside Potential or More
Five biotech stocks are poised for notable growth. Nvidia (NVDA) is the standout performer in the S&P 500 Index so far this year. The biotech industry may be headed for a comeback. Each of these stocks has room to rally 26% to Wall Street's mean price target.
Barchart · 03/07 13:13
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
NASDAQ · 03/04 18:23
Weekly Report: what happened at KNSA last week (0226-0301)?
Weekly Report · 03/04 09:11
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
NASDAQ · 03/01 14:55
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Kiniksa Pharmaceuticals, Ltd. Released its annual results last week. Revenues beat expectations by 4.2% to hit US$270m. The company is forecast to report a loss per share of US$0.15 in 2024. The shares of the company gained 5.7% to US$21.14 after the results. The analysts are now predicting revenues of US $376.5m in 2024 for Kiniks a Pharmaceuticals. There were no major changes to the company's revenue forecasts.
Simply Wall St · 03/01 10:41
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
NASDAQ · 02/29 17:00
New Strong Buy Stocks for February 29th
NASDAQ · 02/29 11:47
More
Webull provides a variety of real-time KNSA stock news. You can receive the latest news about Kiniksa Pharmaceuticals, Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About KNSA
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).